Prof. Dr. med. Georg Schett

Lehrstuhl für Innere Medizin III

APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM (2017) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution Adipocytokine as a Link between Metabolism and Osteoarthritis (2017) Huelser ML, Schreiyaeck C, Luo Y, Bozec A, Schett G, Mueller-Ladner U, Neumann E Conference contribution Dipeptidyl-Peptidase-4 (DPP4) Promotes Fibroblast Activation and Is a Potential Molecular Target for Treatment of Fibrosis (2017) Soare A, Gyoerfy H, Matei AE, Dees C, Chen CW, Ramming A, Schett G, Distler J Conference contribution Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study (2017) Schett G, Lehman T, Ahmad HA, Johnsen A, Banerjee S, Mease PJ Conference contribution Adipocytokines in an Osteoarthritis Mouse Model (2017) Huelser ML, Schreiyaeck C, Luo Y, Bozec A, Schett G, Neumann E, Mueller-Ladner U Conference contribution Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies (2017) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution CORTICAL BONE LOSS IS AN EARLY FEATURE OF AXIAL SPONDYLOARTHRITIS (2017) Haschka J, Neumann A, Kleyer A, Schuster L, Englbrecht M, Figueiredo CP, Muschitz C, et al. Conference contribution PREVALENCE AND CHARACTERISTICS OF SPONDYLOARTHRITIS ACCORDING TO ASAS CRITERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - RESULTS FROM THE SPICE COHORT (2017) Haschka J, Hirschmann S, Kleyer A, Englbrecht M, Zimmermann J, Faustini F, Simon D, et al. Conference contribution Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial (2017) Schenker H, Heß A, Konerth L, Sergeeva M, Prade J, Kleyer A, Reiser M, et al. Conference contribution